The role of GLP-1 receptor agonists in IBD-related surgery and IBD-related complications of inflammatory bowel disease among patients with metabolic comorbidities: a systematic review and meta-analysis

作者：Mengqi Yang, Yujia Huo, Zhining Liu, Guannan Bai, Dong He, Lin Zhang · 发表于：Frontiers in Medicine · 年份：2025 · DOI：10.3389/fmed.2025.1621958 · 被引用次数：4 · 研究领域：Diabetes Treatment and Management、Bariatric Surgery and Outcomes、Inflammatory Bowel Disease

Background Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used for type 2 diabetes and obesity, and emerging evidence suggests potential immunomodulatory effects. However, few studies have evaluated their role in inflammatory bowel disease (IBD), and no comprehensive clinical trials exist. This meta-analysis aimed to assess the association between GLP-1RA use and IBD-related surgeries and complications. Methods A systematic literature search was conducted in PubMed, Embase, and Web of Science from inception to March 2025. Cohort studies comparing IBD patients treated with GLP-1RAs versus non-users were included. Two reviewers independently performed study selection and data extraction. Random-effects meta-analyses were performed using log-transformed effect sizes. Heterogeneity was assessed using I 2 and τ 2 . Publication bias was evaluated through funnel plots, and certainty of evidence was graded using the GRADE framework. Results Six studies were included, providing eight effect estimates (two studies contributed two cohorts each). Three of the six included studies (50%) were non–peer-reviewed conference abstracts, which may affect interpretability. For IBD-related surgery (4 effect estimates), GLP-1RA use was significantly associated with lower risk (pooled estimate: 0.45; 95% CI: 0.35–0.59; I 2 = 38.1%). For IBD-related complications (4 estimates), GLP-1RA use showed a non-significant trend toward benefit (estimate: 0.39; 95% CI: 0.15–1.03), with high he...